Revelstoke Capital Partners Backs AOM Infusion for Enhanced Care
Revelstoke Capital Partners, a private equity firm dedicated to transforming the healthcare landscape, has announced its strategic investment in AOM Infusion. This announcement marks a significant milestone toward enhancing access to specialty infusion therapies. AOM Infusion specializes in managing chronic therapies and has gained recognition for its commitment to patient care.
Transforming Patient Care with Infusion Therapies
AOM Infusion offers patients a wide range of therapies, including Intravenous Immunoglobulin (IVIG) and various biologics, addressing over 80 chronic conditions. The infusion services are delivered by proficient nurses who ensure that patients receive the highest quality care in a comfortable setting. Additionally, the company provides comprehensive support services such as pharmacy management, referral management, and patient education to streamline their infusion therapy experience.
Leadership Perspective on Upcoming Growth
"At Revelstoke, our goal is to collaborate with robust management teams to create leading companies in the healthcare sector," emphasized Anthony Hayes, a Partner at Revelstoke. He expressed confidence in AOM Infusion’s proven business model and the company's record of consistent growth. Revelstoke aims to bolster AOM’s management team as they navigate the next phase of development.
Vision for Future Expansion
Keyur Mehta, CEO of AOM, highlighted the importance of this partnership, stating, "Our commitment to enriching patient care is stronger than ever. With Revelstoke’s backing, we plan to reach beyond current offerings, enhancing our therapeutic focus and deepening our clinical insights to provide effective and personalized care to our patients."
Strategic Focus on Specialty Infusions
As the healthcare industry continues to shift toward outpatient care models, specialty infusion therapies have emerged as a pivotal investment focus for Revelstoke. Eric Hale, Vice President at Revelstoke, pointed out, "We anticipate that AOM is well-positioned to thrive in this evolving environment, given its long-standing track record and innovative approaches to patient treatment. Our interest in AOM spans several years, illustrating our belief in the company’s potential for ongoing success."
Advisory Support for the Transaction
The financial journey for this investment involved significant support from experts in the field. Guggenheim Securities and Houlihan Lokey acted as financial advisors, while McGuireWoods LLP provided legal guidance to Revelstoke. Similarly, Jefferies LLC and Moelis & Company served as financial advisors to AOM, showcasing a comprehensive advisory framework to ensure the seamless progression of this investment.
About AOM Infusion and Revelstoke Capital Partners
AOM Infusion has established itself as a leader in delivering high-quality infusion services for chronic conditions, focusing on an exceptional patient experience. Founded in 1994, the company holds licenses for pharmacy operations in all states, demonstrating its extensive reach and commitment to care quality.
On the other hand, Revelstoke Capital Partners operates as a forward-thinking private equity firm with a keen focus on healthcare services and technology. With about $4.8 billion in assets under management, it aims to foster growth in companies that enhance healthcare delivery. Their robust acquisition strategy has led to a substantial portfolio, comprising numerous successful investments in the healthcare sector since their inception in 2013.
Frequently Asked Questions
1. What is the focus of AOM Infusion?
AOM Infusion specializes in providing infusion therapies, including IVIG and biologics, for chronic conditions.
2. Who are the key figures involved in this partnership?
Anthony Hayes from Revelstoke and Keyur Mehta, the CEO of AOM, are prominent figures discussing this strategic collaboration.
3. What are the support services provided by AOM Infusion?
AOM Infusion offers skilled nursing administration, pharmacy services, referral management, insurance verification, and patient education.
4. Why is Revelstoke Capital Partners interested in AOM Infusion?
Revelstoke sees AOM as well-positioned for future success, especially within the specialty infusion therapy market.
5. When was AOM Infusion founded?
AOM Infusion was founded in 1994 and has since expanded its reach across all 50 states in the U.S.
